EGFR and colorectal cancer: This likely underlies the reduced and more heterogeneous response to inactive-state selective KRASG12C inhibitors that has been observed thus far in colorectal cancer as compared with that in NSCLC, and the significant combination benefit that has been observed for these inhibitors with anti-EGFR antibodies (15, 16).